Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sivelestat sodium for ARDS caused by multiple injuries
ChiCTR2200056205Phase 4Recruiting
- Sponsor
- People's Hospital of Jiangdu
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sivelestat in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by People's Hospital of Jiangdu. Primary endpoint: 28-day case fatality rate. Started Feb 2022; status: recruiting.
02
Drugs
sivelestat
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR2200056205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056205.